Article Sidebar
Views pdf: 0
ASSESSMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH ANKYLOSING SPONDYLITIS ACCORDING TO THE 2022 GUIDELINES OF THE VIETNAM SOCIETY OF CARDIOLOGY
Main Article Content
Abstract
Objectives: 1. Survey 10-year cardiovascular (CV) risk in patients with ankylosing spondylitis (AS) at Bach Mai Hospital acording recommended by the Vietnam Heart Association in 2022. 2. Find out the relationship between cardiovascular risk and selected clinical and paraclinical characteristics of the study subjects. Subjects and Methods: This cross-sectional study was conducted on 71 patients diagnosed with ankylosing spondylitis according to the Modified New York 1984 criteria or ASAS 2009 criteria. Patients were examined or treated at the Musculoskeletal Center and the Outpatient Department of Bach Mai Hospital from August 2024 to July 2025. Results: The 10-year cardiovascular risk in patients with ankylosing spondylitis (AS), assessed according to the 2022 guidelines of the Vietnam National Heart Association: The low–moderate cardiovascular risk group accounted for 47.9%, the high-risk group accounted for 32.4%, the very high-risk group accounted for 19.7%. Cardiovascular risk was associated with several factors including disease activity level, disease duration, and CRP concentration. The high-to-very high-risk group had an average ASDAS score of 2.5 ±0.8, which was higher (reflecting higher disease activity) than the low-to-moderate risk group (ASDAS 2.0 ± 0.7); the average CRP concentration in the high-to-very high-risk group (19.29 ± 23.58mg/L) was about 1.41 times higher than the low-to-moderate risk group (13.65 ± 21.06); the group with disease duration > 5 years had an average cardiovascular risk prediction score of 8.16 ± 7.27%, about 2.48 times higher than the group with disease duration < 5 years, which had a cardiovascular risk prediction score of 3.29 ± 2.46%. Conclusion: Patients with ankylosing spondylitis have a high cardiovascular risk. Several factors are associated with cardiovascular risk in AS patients: disease duration, CRP concentration, and disease activity level. It is necessary to assess cardiovascular risk in patients with ankylosing spondylitis to promptly identify and intervene on risk factors.
Article Details
Keywords
Cardiovascular risk, Spondylo Arthritis, Rheumatoid Arthritis, SCORE-2
References
2. Berg IJ và cộng sự. CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. Ann Rheum Dis. 2015 Aug;74(8):1562-6.
3. Ferraz-Amaro I và cộng sự. Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. Ther Adv Musculoskelet Dis. 2021 Jul 28;13: 1759720X211033755.
4. Ionescu M, Ionescu P, Suceveanu AP, Stoian AP, Motofei I, Ardeleanu V, Parepa IR. Cardiovascular risk estimation in young patients with ankylosing spondylitis: A new model based on a prospective study in Constanta County, Romania. Exp Ther Med. 2021 May;21(5):529.
5. Klisic A, Kotur-Stevuljevic J, Cure O, Kizilkaya B, Beyazal Celiker F, Er H, Mercantepe F. Cardiovascular Risk in Patients with Ankylosing Spondylitis. Journal of Clinical Medicine. 2024; 13(20):6064.
6. Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: An updated meta-analysis. Seminars in Arthritis and Rheumatism. 2015;44(5):551-555. doi:10.1016/j.semarthrit.2014.10.007
7. Navarini, L., Currado, D., Marino, A. et al. Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. Sci Rep 12, 7498 (2022).
8. Sarp Ü, Üstüner E, Kutlay S, Ataman Ş, Kutlay S. Biomarkers of Cardiovascular Disease in Patients With Ankylosing Spondylitis. Arch Rheumatol 2020;35(3):435-439.